Renovorx Stock Performance
| RNXT Stock | USD 0.86 0.03 3.61% |
The company holds a Beta of 2.04, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, RenovoRx will likely underperform. At this point, RenovoRx has a negative expected return of -0.13%. Please make sure to check RenovoRx's potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if RenovoRx performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days RenovoRx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
1 | Is RenovoRx Inc. stock near bottom after decline - 2025 Bull vs Bear Smart Money Movement Tracker - Newser | 12/04/2025 |
2 | Acquisition by Agah Ramtin of 10000 shares of RenovoRx at 0.96 subject to Rule 16b-3 | 12/05/2025 |
3 | Acquisition by Agah Ramtin of 12000 shares of RenovoRx at 0.85 subject to Rule 16b-3 | 12/16/2025 |
4 | Acquisition by Agah Ramtin of 205 shares of RenovoRx at 0.826 subject to Rule 16b-3 | 12/30/2025 |
5 | Acquisition by Agah Ramtin of 9795 shares of RenovoRx at 0.86 subject to Rule 16b-3 | 12/31/2025 |
6 | RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 | 01/08/2026 |
7 | Bear Alert What is RenovoRx Incs book value per share - 2025 Fundamental Recap Reliable Breakout Stock Forecasts - baoquankhu1.vn | 01/15/2026 |
8 | RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center | 01/20/2026 |
9 | Acquisition by Agah Ramtin of 10000 shares of RenovoRx at 0.9975 subject to Rule 16b-3 | 01/21/2026 |
10 | RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting | 01/28/2026 |
11 | Jones Trading initiates coverage on RenovoRx stock with Buy rating By Investing.com - Investing.com India | 01/30/2026 |
12 | Acquisition by Marton Laurence of 25438 shares of RenovoRx at 1.7 subject to Rule 16b-3 | 02/02/2026 |
13 | RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting | 02/04/2026 |
14 | RenovoRx Establishes RenovoCath Medical Advisory Board | 02/10/2026 |
15 | Acquisition by Shaun Bagai of 5000 shares of RenovoRx at 0.9013 subject to Rule 16b-3 | 02/20/2026 |
16 | RenovoRx at a Strategic Crossroads - AD HOC NEWS | 02/23/2026 |
| Begin Period Cash Flow | 1.2 M | |
| Total Cashflows From Investing Activities | -12 K |
RenovoRx Relative Risk vs. Return Landscape
If you would invest 95.00 in RenovoRx on December 4, 2025 and sell it today you would lose (12.00) from holding RenovoRx or give up 12.63% of portfolio value over 90 days. RenovoRx is currently does not generate positive expected returns and assumes 4.5165% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than RenovoRx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RenovoRx Target Price Odds to finish over Current Price
The tendency of RenovoRx Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.86 | 90 days | 0.86 | about 89.88 |
Based on a normal probability distribution, the odds of RenovoRx to move above the current price in 90 days from now is about 89.88 (This RenovoRx probability density function shows the probability of RenovoRx Stock to fall within a particular range of prices over 90 days) .
RenovoRx Price Density |
| Price |
Predictive Modules for RenovoRx
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as RenovoRx. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of RenovoRx's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
RenovoRx Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. RenovoRx is not an exception. The market had few large corrections towards the RenovoRx's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold RenovoRx, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of RenovoRx within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.06 | |
β | Beta against Dow Jones | 2.04 | |
σ | Overall volatility | 0.07 | |
Ir | Information ratio | -0.0042 |
RenovoRx Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of RenovoRx for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for RenovoRx can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| RenovoRx generated a negative expected return over the last 90 days | |
| RenovoRx has some characteristics of a very speculative penny stock | |
| RenovoRx has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 43 K. Net Loss for the year was (8.81 M) with profit before overhead, payroll, taxes, and interest of 629 K. | |
| RenovoRx currently holds about 10.77 M in cash with (9.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| RenovoRx has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: RenovoRx at a Strategic Crossroads - AD HOC NEWS |
RenovoRx Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of RenovoRx Stock often depends not only on the future outlook of the current and potential RenovoRx's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. RenovoRx's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 23.6 M | |
| Cash And Short Term Investments | 7.2 M |
RenovoRx Fundamentals Growth
RenovoRx Stock prices reflect investors' perceptions of the future prospects and financial health of RenovoRx, and RenovoRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RenovoRx Stock performance.
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.68 | ||||
| Operating Margin | (12.03) % | ||||
| Current Valuation | 23.23 M | ||||
| Shares Outstanding | 36.65 M | ||||
| Price To Book | 4.09 X | ||||
| Price To Sales | 34.83 X | ||||
| Revenue | 43 K | ||||
| Gross Profit | 629 K | ||||
| EBITDA | (10.97 M) | ||||
| Net Income | (8.81 M) | ||||
| Cash And Equivalents | 10.77 M | ||||
| Cash Per Share | 1.19 X | ||||
| Total Debt | 278 K | ||||
| Current Ratio | 10.01 X | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (9.12 M) | ||||
| Earnings Per Share | (0.36) X | ||||
| Market Capitalization | 32.32 M | ||||
| Total Asset | 8.12 M | ||||
| Retained Earnings | (50.22 M) | ||||
| Working Capital | 5.92 M | ||||
About RenovoRx Performance
Assessing RenovoRx's fundamental ratios provides investors with valuable insights into RenovoRx's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the RenovoRx is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.25) | (1.31) | |
| Return On Capital Employed | (2.03) | (2.13) | |
| Return On Assets | (1.25) | (1.31) | |
| Return On Equity | (1.77) | (1.68) |
Things to note about RenovoRx performance evaluation
Checking the ongoing alerts about RenovoRx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for RenovoRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RenovoRx generated a negative expected return over the last 90 days | |
| RenovoRx has some characteristics of a very speculative penny stock | |
| RenovoRx has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 43 K. Net Loss for the year was (8.81 M) with profit before overhead, payroll, taxes, and interest of 629 K. | |
| RenovoRx currently holds about 10.77 M in cash with (9.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| RenovoRx has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: RenovoRx at a Strategic Crossroads - AD HOC NEWS |
- Analyzing RenovoRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RenovoRx's stock is overvalued or undervalued compared to its peers.
- Examining RenovoRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RenovoRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of RenovoRx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RenovoRx's stock. These opinions can provide insight into RenovoRx's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.